Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth
Source: SeekingAlpha
2026-01-22 13:05:49 ET
Bio-Rad's ( BIO ) ( BIO.B ) management has been taking steps to improve its long-term core growth prospects, but it takes time for those steps to translate into real results. Meanwhile, the company has to deal with challenging end-market conditions, including considerable funding uncertainties for academic labs and biotechs, as well as global tariffs....
Read the full article on Seeking Alpha
For further details see:
Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth
Bio-Rad Laboratories Inc. Class A
NASDAQ: BIO
BIO Trading
11.5% G/L:
$277.42 Last:
471,754 Volume:
$274.72 Open:
BIO Latest News
BIO Stock Data
$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules
